CY1111017T1 - USE OF PIPAMERONIS AND A D-2 COMPETITOR OR SEROTONIN / DOPAMIN COMPONENT OR COMPETITOR FOR THE TREATMENT OF PSYCHOLOGICAL DISORDERS - Google Patents
USE OF PIPAMERONIS AND A D-2 COMPETITOR OR SEROTONIN / DOPAMIN COMPONENT OR COMPETITOR FOR THE TREATMENT OF PSYCHOLOGICAL DISORDERSInfo
- Publication number
- CY1111017T1 CY1111017T1 CY20101100611T CY101100611T CY1111017T1 CY 1111017 T1 CY1111017 T1 CY 1111017T1 CY 20101100611 T CY20101100611 T CY 20101100611T CY 101100611 T CY101100611 T CY 101100611T CY 1111017 T1 CY1111017 T1 CY 1111017T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- competitor
- partial
- hypersensitivity
- antagonistic
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αφορά την χρήση ενώσεων και συνθέσεων ενώσεων που έχουν D4 και 5-ΗΤ2Α ανταγωνιστική, μερική αγωνιστική ή ανάστροφη αγωνιστική δραστικότητα για την θεραπεία της υποκείμενης δυσλειτουργίας της συναισθηματικής λειτουργικότητας των διανοητικών διαταραχών (δηλ. αποτέλεσμα αστάθειας - υπερευαισθησίας - υπεραισθησίας- ψυχοδιασπαστικών φαινομένων- κ.τ.λ). Η εφεύρεση επίσης αφορά μεθόδους που περιλαμβάνουν χορήγηση σε έναν ασθενή, που έχει διαγνωστεί ως έχων μία νευροψυχιατρική διαταραχή, μιας φαρμακευτικής σύνθεσης που περιέχει (i) ενώσεις που έχουν D4 ανταγωνιστική, μερική αγωνιστική ή ανάστροφη αγωνιστική δραστικότητα και (ii) ενώσεις που έχουν 5-ΗΤ2Α ανταγωνιστική, μερική αγωνιστική ή ανάστροφη αγωνιστική δραστικότητα και (iii) οποιαδήποτε γνωστή ιατρική ένωση και συνθέσεις των εν λόγω ενώσεων. Τα συνδυασμένα D4 και 5-ΗΤ2Α ανταγωνιστικά, μερικά αγωνιστικά ή ανάστροφα αγωνιστικά αποτελέσματα μπορεί να βασίζονται στην ίδια χημική ή βιολογική ένωση ή σε δύο διαφορετικές χημικές ή/και βιολογικές ενώσεις.The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonist activity to treat the underlying dysfunction of emotional functioning of mental disorders (i.e., hypersensitivity-hypersensitivity-hypersensitivity- etc.). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition comprising (i) compounds having D4 antagonistic, partial agonist or reverse agonist activity and (ii) compounds having 5- HT2A antagonist, partial agonist or reverse agonist activity and (iii) any known medical compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial or reverse agonist effects may be based on the same chemical or biological compound or two different chemical and / or biological compounds.
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/725,965 US7884096B2 (en) | 2003-12-02 | 2003-12-02 | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA2451798A CA2451798C (en) | 2003-12-02 | 2003-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP03447279A EP1547650A1 (en) | 2003-12-02 | 2003-12-02 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP04447001 | 2004-01-05 | ||
| US10/752,423 US7855195B2 (en) | 2003-12-02 | 2004-01-06 | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US10/803,793 US20050119249A1 (en) | 2003-12-02 | 2004-03-18 | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP04447066A EP1576985A1 (en) | 2004-03-18 | 2004-03-18 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA 2461248 CA2461248C (en) | 2003-12-02 | 2004-03-18 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP04025035A EP1541197B8 (en) | 2003-12-02 | 2004-10-21 | Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders |
| JP2004349085A JP4571485B2 (en) | 2003-12-02 | 2004-11-04 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US10/984,683 US20050203130A1 (en) | 2003-12-02 | 2004-11-09 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA 2487529 CA2487529A1 (en) | 2003-12-02 | 2004-11-15 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP04801138A EP1708790B1 (en) | 2003-12-02 | 2004-12-02 | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111017T1 true CY1111017T1 (en) | 2015-06-11 |
Family
ID=53717448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100611T CY1111017T1 (en) | 2003-12-02 | 2010-07-05 | USE OF PIPAMERONIS AND A D-2 COMPETITOR OR SEROTONIN / DOPAMIN COMPONENT OR COMPETITOR FOR THE TREATMENT OF PSYCHOLOGICAL DISORDERS |
Country Status (1)
| Country | Link |
|---|---|
| CY (1) | CY1111017T1 (en) |
-
2010
- 2010-07-05 CY CY20101100611T patent/CY1111017T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110316T1 (en) | USE OF PIPAMERONIS AND AN SNDRI, SNRI Ή SSRI FOR MENTAL DISORDERS OR ANXIETY TREATMENT | |
| CY1113159T1 (en) | COMPETITIVES OF GLUCAGON COMPETITIVES, PREPARATION AND HEALTH USES | |
| CY1112376T1 (en) | 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists | |
| CY1109860T1 (en) | FACTORS OF HISTAMIN H3 CONTAINERS, PREPARATION AND THERAPEUTIC USES | |
| EA200401284A1 (en) | SUBSTITUTED BENZEZOLES AND THEIR APPLICATION AS RAF KINASE INHIBITORS AS AN INHIBITORS | |
| DE60315677D1 (en) | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA TEMPERATURES FOR THE TREATMENT OF CANCER | |
| CY1110965T1 (en) | ADDITIONAL HYPERPYROCYCLIC COMPOUNDS AND THEIR USE AS GLUTAMIC METHOD | |
| EA200700027A1 (en) | GLUCAGON RECEPTOR ANTAGONISTS, THEIR RECEIVING AND THERAPEUTIC APPLICATION | |
| ATE508114T1 (en) | ISOINDOLYL COMPOUNDS SUBSTITUTED WITH N-ALKYLHYDROXAMIC ACIDS AND THEIR PHARMACEUTICAL USE | |
| EA200301215A1 (en) | 5-HT RECEPTOR LIGANDS AND THEIR APPLICATION | |
| EA200501430A1 (en) | Cannabinoid receptor ligands and their use | |
| BRPI0418099A (en) | compounds, pharmaceutical composition, and use of a compound | |
| CY1110922T1 (en) | COMPETITIVES OF GLUCAGON COMPETITORS, PREPARATION AND HEALTH USES | |
| CY1106600T1 (en) | ABRASION RESISTANT CO-EXPORTED DOSAGE FORM CONTAINING AN ACTIVE AGENT AND A COMPETITIVE AGENT AND PROCESS FOR THE PREPARATION THEREOF | |
| BRPI0514661A (en) | vasopressin antagonists v1a | |
| EA200970302A1 (en) | TIOPHENPYRAZOLOPIRIMIDIN COMPOUNDS | |
| SV2005002148A (en) | "MODULATING COMPOUNDS OF THE C-KIT ACTIVITY AND USES OF THE SAME" | |
| CY1108421T1 (en) | THE USE OF MELOXICAM PREPARATIONS IN VETERINARY | |
| CR7928A (en) | MEDICATION FOR PROPHYLAXIS AND TREATMENT OF ARTERIOSCLEROSIS AND HYPERTENSION | |
| EA200970303A1 (en) | TIAZOLEPRAZOLOPRIMIDINE IN QUALITY ANTAGONISTIC RECEPTOR CRF1 | |
| EA200500286A1 (en) | NEW ISOTIAZOLE AND ISOXASOLIC COMPOUNDS AS AN INHIBITORS TRANSFORMING GROWTH FACTOR (TGF) | |
| DE602006015509D1 (en) | Glucagonone receptor agonists, their preparation and their therapeutic use | |
| EA200500803A1 (en) | CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY ARTHRITIS, DEMIELINIZATION INFLAMMATORY DISEASES | |
| EA200501821A1 (en) | PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION | |
| ECSP045397A (en) | 6-ALQUILIDEN-BICYCLIC PENEMS AS INHIBITORS OF THE B-LACTAMASES |